Literature DB >> 30637468

Human parechovirus meningitis and gross-motor neurodevelopment in young children.

Ted M T van Hinsbergh1, Stephanie C M de Crom2, Robert Lindeboom3, Marceline A M van Furth4, Charlie C Obihara5.   

Abstract

This multicenter prospective cohort study describes the impact of human parechovirus meningitis on gross-motor neurodevelopment of young children. Gross-motor function was measured using Alberta Infant Motor Scale. Of a total of 38 eligible children < 10 months of age at onset, nine cases had clinical evidence of meningitis and polymerase chain reaction positive for human parechovirus in cerebrospinal fluid; 11 had no meningitis and polymerase chain reaction positive for human parechovirus in nasopharyngeal aspirate, blood, urine, or feces; and in 18, no pathogen was identified (reference group).The children with human parechovirus meningitis showed more frequent albeit not statistically significant suspect gross-motor function delay (mean Z-score (standard deviation) - 1.69 (1.05)) than children with human parechovirus infection-elsewhere (- 1.38 (1.51)). The reference group did not fall in the range of suspect gross-motor function delay (- 0.96 (1.07)). Adjustment for age at onset and maternal education did not alter the results.
Conclusion: Six months after infection, children with human parechovirus meningitis showed more frequent albeit not statistically significant suspect gross-motor function delay compared to the population norm and other two groups. Longitudinal studies in larger samples and longer follow-up periods are needed to confirm the impact and persistence of human parechovirus meningitis on neurodevelopment in young children. What is Known: • Human parechovirus is progressively becoming a major viral cause of meningitis in children. • There is keen interest in the development of affected infants with human parechovirus meningitis. What is New: • This study describes prospectively gross-motor functional delay in children with both clinical evidence of meningitis and polymerase chain reaction positive for human parechovirus in cerebrospinal fluid. • It shows the importance of screening young children for developmental delay in order to refer those with delay for early intervention to maximize their developmental potential.

Entities:  

Keywords:  Children; Human parechovirus; Meningitis; Neurodevelopment

Mesh:

Year:  2019        PMID: 30637468     DOI: 10.1007/s00431-019-03319-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.860


  29 in total

1.  The neuronal group selection theory: a framework to explain variation in normal motor development.

Authors:  M Hadders-Algra
Journal:  Dev Med Child Neurol       Date:  2000-08       Impact factor: 5.449

2.  Two cases of neonatal human parechovirus 3 encephalitis.

Authors:  Elena Pariani; Laura Pellegrinelli; Lorenza Pugni; Paolo Bini; Simona Perniciaro; Laura Bubba; Valeria Primache; Antonella Amendola; Mario Barbarini; Fabio Mosca; Sandro Binda
Journal:  Pediatr Infect Dis J       Date:  2014-11       Impact factor: 2.129

3.  Comparison of diagnostic clinical samples and environmental sampling for enterovirus and parechovirus surveillance in Scotland, 2010 to 2012.

Authors:  H Harvala; J Calvert; D Van Nguyen; L Clasper; N Gadsby; P Molyneaux; K Templeton; C McWilliams Leitch; P Simmonds
Journal:  Euro Surveill       Date:  2014-04-17

4.  Human Parechovirus Meningitis with Adverse Neurodevelopmental Outcome: A Case Report.

Authors:  Mylene C Berk; Andrea H L Bruning; Aleid G van Wassenaer-Leemhuis; Katja C Wolthers; Dasja Pajkrt
Journal:  Pediatr Infect Dis J       Date:  2018-10       Impact factor: 2.129

5.  Impaired postural control in children with developmental coordination disorder is related to less efficient central as well as peripheral control.

Authors:  Merete B Speedtsberg; Sofie B Christensen; Ken Kjøller Andersen; Jesper Bencke; Bente R Jensen; Derek J Curtis
Journal:  Gait Posture       Date:  2016-09-24       Impact factor: 2.840

6.  Molecular epidemiology of enterovirus and parechovirus infections according to patient age over a 4-year period in Spain.

Authors:  María Cabrerizo; María Díaz-Cerio; Carmen Muñoz-Almagro; Núria Rabella; David Tarragó; María Pilar Romero; María José Pena; Cristina Calvo; Sonia Rey-Cao; Antonio Moreno-Docón; Inés Martínez-Rienda; Almudena Otero; Gloria Trallero
Journal:  J Med Virol       Date:  2016-08-22       Impact factor: 2.327

7.  Specific cell tropism and neutralization of human parechovirus types 1 and 3: implications for pathogenesis and therapy development.

Authors:  Brenda M Westerhuis; Gerrit Koen; Joanne G Wildenbeest; Dasja Pajkrt; Menno D de Jong; Kimberley S M Benschop; Katja C Wolthers
Journal:  J Gen Virol       Date:  2012-07-25       Impact factor: 3.891

8.  Parechovirus Encephalitis and Neurodevelopmental Outcomes.

Authors:  Philip N Britton; Russell C Dale; Michael D Nissen; Nigel Crawford; Elizabeth Elliott; Kristine Macartney; Gulam Khandaker; Robert Booy; Cheryl A Jones
Journal:  Pediatrics       Date:  2016-01-20       Impact factor: 7.124

9.  Prospective comparison of the detection rates of human enterovirus and parechovirus RT-qPCR and viral culture in different pediatric specimens.

Authors:  S C M de Crom; C C Obihara; R A de Moor; E J M Veldkamp; A M van Furth; J W A Rossen
Journal:  J Clin Virol       Date:  2013-08-21       Impact factor: 3.168

10.  Outcome of routine cerebrospinal fluid screening for enterovirus and human parechovirus infection among infants with sepsis-like illness or meningitis in Cornwall, UK.

Authors:  Prithwiraj Chakrabarti; Chris Warren; Laura Vincent; Yadlapalli Kumar
Journal:  Eur J Pediatr       Date:  2018-07-18       Impact factor: 3.860

View more
  1 in total

Review 1.  Etiology, Clinical Phenotypes, Epidemiological Correlates, Laboratory Biomarkers and Diagnostic Challenges of Pediatric Viral Meningitis: Descriptive Review.

Authors:  Saleh M Al-Qahtani; Ayed A Shati; Youssef A Alqahtani; Abdelwahid Saeed Ali
Journal:  Front Pediatr       Date:  2022-06-16       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.